Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The company plans to expand their capacity to meet the needs of pharma and biotech industries
This is the fourth facility from the company to receive this registration
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
Sputnik M is a new member of the Sputnik vaccines family
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Subscribe To Our Newsletter & Stay Updated
